Mediphage Bioceuticals appoints Alvaro Amorrortu as chief executive officer and president

Written By Maura Campbell
mediphage.png

Mediphage Bioceuticals, a non-viral gene therapy company, developing effective, and highly-scalable therapeutics to unlock the power of safe and redosable genetic medicines, announced the appointment of Alvaro Amorrortu as its chief executive officer and president.

Maura Campbell
Previous

AmacaThera announces Phase 1 clinical trial for non-opioid, post-operative pain management
Next

Microbix announces $1.45 million grant for production of critical test reagents